deltatrials
Terminated PHASE2/PHASE3 NCT00084240

Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia

A Phase 2/3, Randomized, Comparative, Double Blind Trial Of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia

Sponsor: Pfizer

Conditions Malaria, Falciparum
Interventions Azithromycin/Chloroquine Sulfadoxine-Pyrimethamine/Chloroquine
Updated 5 times since 2017 Last updated: Oct 30, 2008 Started: Mar 31, 2004 Completion: Apr 30, 2005

This PHASE2/PHASE3 trial investigates Malaria, Falciparum and is currently terminated or withdrawn. Pfizer leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2_PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2_PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2_PHASE3

    First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.